SCHEMBL25544357

SCHEMBL25544357

Cc1ccc2c(-c3ccc(F)c(C)c3)c(C3=CCOCC3)cnc2c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 2/20 0.39
MAPK14 Q16539 10/20 0.39
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
CSNK1E P49674 4/20 0.39
PDE10A Q9Y233 2/20 0.36
GRIN2B Q13224 5/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
GRIN1 Q05586 1/20 0.34
KCNH2 Q12809 1/20 0.34
SERPINA2 P20848 1/20 0.33
PIK3CB P42338 1/20 0.33
MTOR P42345 1/20 0.33
ATR Q13535 1/20 0.33
ATRIP Q8WXE1 1/20 0.33
CSNK1D P48730 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544355 0.90 PRKDC (0.40) PRKDCMAPK14PDE3BPDE3ACSNK1E
SCHEMBL25544752 0.89 MAPK14 (0.39) PRKDCMAPK14PDE3BPDE3ACSNK1E
SCHEMBL23888028 0.83 TLR8 (0.39) PRKDCMAPK14PDE3BPDE3APDE10A
SCHEMBL25544932 0.78 MAPK14 (0.36) PRKDCMAPK14PDE3BPDE3ACSNK1E
SCHEMBL25544361 0.77 PDE10A (0.39) MAPK14PDE3BPDE3ACSNK1EPDE10A
SCHEMBL25544354 0.74 GRIN2B (0.41) PRKDCGRIN2BCYP1A2CYP2C9CYP2C19
SCHEMBL25544325 0.72 GRIN2B (0.40) GRIN2BGRIN1
SCHEMBL25544328 0.71 CSF1R (0.39) GRIN2BGRIN1KCNH2
SCHEMBL30367978 0.69 GRM4 (0.38) MAPK14CSNK1ECSNK1D
SCHEMBL23887884 0.69 GRM4 (0.38) MAPK14CSNK1ECSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 PRKDC 4039/4885MAPK14 3750/4885PDE3B 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.